- Home
- NHS vs CATX Comparison
NHS vs CATX Comparison
Compare NHS & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- CATX
- Stock Information
- Founded
- NHS 2003
- CATX 1983
- Country
- NHS United States
- CATX United States
- Employees
- NHS N/A
- CATX N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- CATX Medical/Dental Instruments
- Sector
- NHS Finance
- CATX Health Care
- Exchange
- NHS Nasdaq
- CATX Nasdaq
- Market Cap
- NHS 226.7M
- CATX 239.0M
- IPO Year
- NHS N/A
- CATX N/A
- Fundamental
- Price
- NHS $7.35
- CATX $2.99
- Analyst Decision
- NHS
- CATX Strong Buy
- Analyst Count
- NHS 0
- CATX 11
- Target Price
- NHS N/A
- CATX $13.00
- AVG Volume (30 Days)
- NHS 111.8K
- CATX 1.5M
- Earning Date
- NHS 01-01-0001
- CATX 11-11-2025
- Dividend Yield
- NHS 13.44%
- CATX N/A
- EPS Growth
- NHS N/A
- CATX N/A
- EPS
- NHS N/A
- CATX N/A
- Revenue
- NHS N/A
- CATX $1,235,000.00
- Revenue This Year
- NHS N/A
- CATX N/A
- Revenue Next Year
- NHS N/A
- CATX N/A
- P/E Ratio
- NHS N/A
- CATX N/A
- Revenue Growth
- NHS N/A
- CATX N/A
- 52 Week Low
- NHS $6.95
- CATX $1.60
- 52 Week High
- NHS $9.17
- CATX $12.90
- Technical
- Relative Strength Index (RSI)
- NHS 45.10
- CATX 37.64
- Support Level
- NHS $7.14
- CATX $2.85
- Resistance Level
- NHS $7.36
- CATX $5.14
- Average True Range (ATR)
- NHS 0.13
- CATX 0.49
- MACD
- NHS -0.01
- CATX -0.18
- Stochastic Oscillator
- NHS 40.82
- CATX 4.91
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.